Tammy Gardell, APRN
Adult Health · Shirley, MANPI 1558517086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 30.7% of the total. Reporting peaked in 2023 at $1,415 and has fallen 63.4% since, to $518 in 2025. Among adult health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$961
- Novo Nordisk$811
- Nestle Healthcare Nutrition Inc.$251
- AstraZeneca$248
- Abbott$232
- plus $1K from 11 others
What the payments were for
- Food & beverage$5,15099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $1,590 |
| Lilly USA, LLC | 53 | $961 |
| Novo Nordisk | 49 | $811 |
| Nestle Healthcare Nutrition Inc. | 12 | $251 |
| AstraZeneca | 10 | $248 |
| Abbott | 12 | $232 |
| Boehringer Ingelheim | 8 | $223 |
| Exact Sciences | 9 | $185 |
| Sumitomo Pharma America, Inc. | 8 | $148 |
| Phathom Pharmaceuticals, Inc. | 6 | $129 |
| Shield Therapeutics Inc | 6 | $110 |
| Ardelyx, Inc. | 6 | $110 |
| Pfizer | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Mylan Specialty L.p. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$5,182 in reported general payments places this provider in the 95th percentile of 671 adult health providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 59 | $78,211 |
| OzempicSemaglutide | 62 | $66,144 |
| JardianceEmpagliflozin | 75 | $66,086 |
| EliquisApixaban | 66 | $59,245 |
| LinzessLinaclotide | 76 | $55,534 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $32,449 |
| CreonLipase/Protease/Amylase | 25 | $23,916 |
| MounjaroTirzepatide | 21 | $22,580 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $20,436 |
| WegovySemaglutide | 12 | $20,024 |
| Spiriva RespimatTiotropium Bromide | 28 | $15,796 |
| EntrestoSacubitril/Valsartan | 19 | $13,822 |
| Lidocaine | 182 | $13,054 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 48 | $11,873 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $11,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $223 | $109,670151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $961 | $100,79180 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $811 | $97,59286 claims |
| AbbVieLinzess, Creon | $1,590 | $79,450101 claims |
| PfizerEliquis | $93 | $59,24566 claims |
| AstraZenecaBreztri Aerosphere | $248 | $11,72612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 671 adult health providers in Massachusetts.
Other adult health in Shirley
- Krista TuckerBoston$157K
- Kathleen Dietz LovettHyannis$123K
- Caitlin ReenCharlestown$89K
- Tiffini ReedyFall River$58K
- Christine AgiusBoston$32K
- Amy PierreJamaica Plain$27K
- Josie BazemoreBoston$22K
- Jill TerrienWorcester$18K
- Beverly HarrisGroton$15K
- Kelly GoodwinFranklin$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.